Trident Lifeline reported a strong Q2 FY27, with consolidated revenue rising 50% to Rs 47.1 crore and PAT growing 30% to Rs 6.6 crore. The company announced a new preferential issue and expects to commission its parenterals facility post-Diwali to support a three-year growth target.
Trident Lifeline Reports 50% Revenue Growth in Q2
Consolidated revenue climbed to Rs 47.1 crore, while Profit After Tax (PAT) reached Rs 6.6 crore.
Reader Takeaway: Revenue momentum and margin expansion drive growth, but investors should monitor execution timelines for the new facility.
What just happened
Trident Lifeline Ltd has posted robust consolidated results for Q2 FY27. Revenue from operations increased by 50% YoY to Rs 47.1 crore, while EBITDA surged 65% to Rs 11.3 crore. The EBITDA margin improved to 24.1%, up 217 bps from the same period last year. The company also confirmed plans for a preferential issue of securities to bolster its capital base for future growth.
Why this matters
The double-digit growth in both revenue and profit underscores the firm's expanding product portfolio and successful market penetration. Management reaffirmed a long-term goal to triple the business size within three years. The upcoming commissioning of a new parenterals facility, expected shortly after Diwali, is a critical pillar of this growth strategy.
Risks to watch
While the company is scaling, operational delays in commissioning the new parenterals facility remain a primary risk. Additionally, while YoY margins have improved, the company experienced a slight sequential (QoQ) contraction in both EBITDA and PAT margins compared to Q1 FY27, which investors should monitor in the coming quarters.
What to track next
Shareholders should look for the official announcement regarding the terms and pricing of the proposed preferential issue. Furthermore, operational updates regarding the timely commissioning of the parenterals facility will be vital for assessing whether the company can maintain its current growth trajectory.